Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125272611 | 12527261 | 1 | I | 20160621 | 20160705 | 20160705 | EXP | FR-VIIV HEALTHCARE LIMITED-FR2014GSK055293 | VIIV | RENET S, CLOSON A, BROCHET MS, BUSSIERES JF, BOUCHER M. INCREASE IN TRANSAMINASE LEVELS FOLLOWING THE USE OF RALTEGRAVIR IN A WOMAN WITH A HIGH HIV VIRAL LOAD AT 35 WEEKS OF PREGNANCY.. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA. 2013;35 (1):68-72 | 0.00 | I | M | Y | 3.17000 | KG | 20160705 | COUNTRY NOT SPECIFIED | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125272611 | 12527261 | 1 | PS | COMBIVIR | LAMIVUDINEIDOVUDINE | 1 | U | 20857 | TABLET | ||||||||||
| 125272611 | 12527261 | 2 | SS | COTRIMOXAZOLE | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | U | 0 | TABLET | ||||||||||
| 125272611 | 12527261 | 3 | SS | RALTEGRAVIR. | RALTEGRAVIR | 1 | Y | 0 | TABLET | ||||||||||
| 125272611 | 12527261 | 4 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | U | 0 | TABLET | ||||||||||
| 125272611 | 12527261 | 5 | SS | FERROUS SULFATE. | FERROUS SULFATE | 1 | U | 0 | |||||||||||
| 125272611 | 12527261 | 6 | SS | Cefazoline | CEFAZOLIN SODIUM | 1 | U | 0 | SOLUTION FOR INJECTION | ||||||||||
| 125272611 | 12527261 | 7 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | U | 0 | SOLUTION FOR INJECTION | ||||||||||
| 125272611 | 12527261 | 8 | SS | NEVIRAPINE. | NEVIRAPINE | 1 | Oral | 6.3 MG, SINGLE | U | 0 | 6.3 | MG | |||||||
| 125272611 | 12527261 | 9 | SS | NELFINAVIR | NELFINAVIR | 1 | Oral | 126.5 MG, BID | U | 0 | 126.5 | MG | BID | ||||||
| 125272611 | 12527261 | 10 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Oral | 6.3 MG, QID | U | 0 | 6.3 | MG | ORAL SOLUTION | QID | |||||
| 125272611 | 12527261 | 11 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Oral | 6.3 MG, BID | U | 0 | 6.3 | MG | ORAL SOLUTION | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125272611 | 12527261 | 1 | HIV infection |
| 125272611 | 12527261 | 2 | Prophylaxis |
| 125272611 | 12527261 | 3 | HIV infection |
| 125272611 | 12527261 | 4 | HIV infection |
| 125272611 | 12527261 | 5 | Anaemia |
| 125272611 | 12527261 | 6 | Product used for unknown indication |
| 125272611 | 12527261 | 7 | HIV infection |
| 125272611 | 12527261 | 8 | Prophylaxis against HIV infection |
| 125272611 | 12527261 | 9 | Prophylaxis against HIV infection |
| 125272611 | 12527261 | 10 | Prophylaxis against HIV infection |
| 125272611 | 12527261 | 11 | Prophylaxis against HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125272611 | 12527261 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125272611 | 12527261 | Blood urea decreased | |
| 125272611 | 12527261 | Blood uric acid increased | |
| 125272611 | 12527261 | Foetal exposure during pregnancy | |
| 125272611 | 12527261 | Neutrophil count decreased | |
| 125272611 | 12527261 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |